This question tests understanding of beta-blocker receptor selectivity and contraindications. The key patient-specific factor is the history of asthma requiring albuterol use in a patient started on propranolol. Nonselective β blockade inhibiting β2-mediated bronchodilation (B) is correct - propranolol blocks both β1 and β2 receptors, antagonizing β2-mediated bronchodilation and potentially triggering severe bronchospasm in asthmatic patients. Selective β1 blockade causing reflex tachycardia (A) is incorrect as propranolol is nonselective and actually causes bradycardia. α1 agonism (C) and muscarinic antagonism (D) are not mechanisms of propranolol. The clinical framework is that nonselective beta-blockers (propranolol, nadolol, timolol) are contraindicated in asthma and COPD; if beta-blockade is necessary for anxiety in asthmatic patients, highly β1-selective agents like atenolol or metoprolol at low doses may be cautiously tried with close monitoring.

This question tests levothyroxine dose adjustment based on thyroid function tests. The key patient-specific factors are the suppressed TSH (0.05 mIU/L) and elevated free T4 (2.3 ng/dL) indicating iatrogenic hyperthyroidism after a recent dose increase. Decreasing levothyroxine to 100 mcg daily and rechecking TSH in 6-8 weeks (C) is correct - the patient is over-replaced with symptoms of hyperthyroidism requiring dose reduction back to the previous dose. Increasing to 150 mcg (A) would worsen hyperthyroidism. Continuing current dose with early recheck (B) is inappropriate as TSH takes 6-8 weeks to equilibrate after dose changes. Stopping levothyroxine and starting methimazole (D) is incorrect as this is medication-induced, not primary hyperthyroidism. The clinical framework is that levothyroxine has a half-life of 7 days, requiring 6-8 weeks to reach steady state; elderly patients often require 20-30% lower doses; and calcium supplements should be separated by 4 hours to avoid chelation.

This question tests knowledge of pharmacogenetic testing in HIV treatment. The key patient-specific factor is the family history of severe reaction to abacavir and the plan to start an abacavir-containing regimen. HLA-B57:01 positivity (A) is correct - this genetic variant is strongly associated with abacavir hypersensitivity syndrome, occurring in about 5-8% of patients, with nearly 100% negative predictive value when absent. CYP2C19 polymorphisms (B) affect clopidogrel activation, not abacavir. SLCO1B1 variants (C) affect statin myopathy risk, not warfarin sensitivity. CYP2D6 status (D) doesn't significantly affect simvastatin, which is primarily metabolized by CYP3A4. The clinical framework is that HLA-B57:01 testing is mandatory before starting abacavir per HIV treatment guidelines, and patients who test positive should never receive abacavir due to risk of potentially fatal hypersensitivity reaction.

This question tests lithium monitoring principles in the setting of drug-induced toxicity. The key patient-specific factors are the toxic lithium level (1.9 mEq/L), acute kidney injury (SCr 1.6 mg/dL), and recent NSAID initiation. Obtaining a 12-hour post-dose trough level and monitoring renal function (B) is correct - lithium levels must be drawn 12 hours post-dose for accurate interpretation, and renal function monitoring is crucial as lithium is 100% renally eliminated. Random levels 1 hour post-dose (A) are not standardized and will be falsely elevated. Liver function monitoring (C) is incorrect as lithium undergoes no hepatic metabolism. INR monitoring (D) is irrelevant as lithium doesn't affect coagulation. The clinical framework is that NSAIDs reduce renal lithium clearance by 20-60% through prostaglandin inhibition; lithium toxicity presents with GI, neurologic, and renal symptoms; management includes holding lithium and NSAIDs, IV hydration, and serial lithium levels every 6-12 hours.

This question tests understanding of the dangerous drug interaction between ACE inhibitors and potassium-sparing diuretics. The key patient-specific factor is the baseline hyperkalemia (K 5.6 mEq/L) in a patient already on spironolactone, a potassium-sparing diuretic. Avoiding lisinopril until hyperkalemia is corrected (C) is the safest approach because adding an ACE inhibitor to spironolactone significantly increases hyperkalemia risk through dual mechanisms of reducing potassium excretion. Starting lisinopril with potassium supplementation (A) would dangerously worsen hyperkalemia. Reducing furosemide (B) is inappropriate as it helps promote potassium excretion and ACE inhibitor cough is unrelated to diuretic dose. Increasing spironolactone (D) would further elevate potassium levels. The clinical framework is to always check baseline potassium before starting ACE inhibitors/ARBs in patients on potassium-sparing diuretics, and consider temporarily holding or reducing the potassium-sparing agent when initiating RAAS blockade.

This question tests understanding of niacin's mechanism for causing flushing, a common side effect. The key patient-specific factor is the timing of symptoms (30 minutes after first dose) and the characteristic presentation of facial flushing and itching. Prostaglandin-mediated vasodilation from increased PGD2/PGE2 release in the skin (B) is the correct mechanism - niacin activates GPR109A receptors on epidermal Langerhans cells, triggering prostaglandin release and cutaneous vasodilation. Competitive inhibition of HMG-CoA reductase (A) describes statins' mechanism, not niacin's side effect profile. Bile acid chelation (C) describes bile acid sequestrants like cholestyramine. PPAR-α activation (D) describes fibrates' mechanism of action. The clinical takeaway is that pre-treatment with aspirin 325 mg 30 minutes before niacin can reduce flushing by inhibiting prostaglandin synthesis, and extended-release formulations cause less flushing than immediate-release.

This question tests management of a significant warfarin drug interaction. The key patient-specific factor is the dangerously elevated INR of 5.8 (goal 2.5-3.5) after starting TMP-SMX, without active bleeding. Holding warfarin and arranging prompt INR recheck (B) is correct - TMP-SMX inhibits CYP2C9, reducing warfarin metabolism and dramatically increasing INR, requiring immediate dose adjustment to prevent bleeding. Continuing both drugs (A) risks major bleeding with INR 5.8. Increasing warfarin (C) would worsen the supratherapeutic INR. Adding aspirin (D) would increase bleeding risk without addressing the elevated INR. The clinical framework is that TMP-SMX typically increases INR by 2-3 fold within 3-5 days through CYP2C9 inhibition; proactive warfarin dose reduction by 25-50% when starting TMP-SMX, with INR checks every 2-3 days, can prevent this dangerous interaction.

This question tests the pharmacokinetic adjustment of gabapentin in renal impairment, as it is primarily renally excreted unchanged. The key patient-specific factor is the patient's CKD stage 4 with CrCl 22 mL/min, which reduces gabapentin clearance and increases toxicity risk. Using a reduced total daily dose with extended dosing interval (e.g., 300 mg PO once daily to BID) is the best choice to maintain efficacy while preventing accumulation and side effects like sedation. No adjustment is incorrect as it ignores renal dosing guidelines, and avoiding gabapentin due to hepatic clearance is wrong since it is renally cleared; increasing the dose would worsen toxicity. Clinically, calculate CrCl and consult renal dosing resources for gabapentin, typically reducing to 100–300 mg daily for CrCl <30 mL/min. In practice, monitor for CNS side effects and titrate slowly in CKD patients to optimize neuropathy management.

This question tests the pharmacokinetic induction of warfarin metabolism by rifampin, a potent CYP3A4 and CYP2C9 inducer, reducing anticoagulant effect. The key patient-specific factor is the subtherapeutic INR of 1.4 after 2 weeks of rifampin in a patient with a mechanical valve requiring higher INR goals. Increasing warfarin dose with very frequent INR monitoring during rifampin therapy is the best approach to restore therapeutic anticoagulation and prevent thrombosis. Decreasing warfarin is incorrect as it would further lower INR, and continuing unchanged or adding fluconazole ignores the induction effect. Clinically, anticipate up to 2–3 fold warfarin dose increases with rifampin, monitoring INR weekly initially. In practice, consider alternative anticoagulants like DOACs if induction interactions are unavoidable to maintain efficacy.

This question tests the diuretic side effects of SGLT2 inhibitors like empagliflozin, promoting urinary glucose excretion. The key patient-specific factor is type 2 diabetes with recent empagliflozin start, causing polyuria and thirst from osmotic diuresis. Inhibition of SGLT2 in the proximal tubule causing glucosuria and osmotic diuresis is the correct mechanism, explaining the symptoms despite improving glucose control. DPP-4 blockade or PPAR-γ activation cause different effects like edema, not diuresis; insulin stimulation does not directly cause water loss. Clinically, counsel on transient volume depletion and monitor for dehydration. In practice, assess electrolytes and encourage hydration to manage SGLT2i side effects in diabetes care.